Lanosterol 14-alpha demethylase · SINGLE PROTEIN · Fungi
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by vulvovaginal candidiasis. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P10613. Start with vulvovaginal candidiasis, then reuse UniProt P10613 as the stable protein anchor across project notes and exports.
Start with vulvovaginal candidiasis, then reuse UniProt P10613 as the stable protein anchor across project notes and exports.
Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by vulvovaginal candidiasis. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with vulvovaginal candidiasis because it currently carries approved-linked support. Linked drugs include OTESECONAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLanosterol 14-alpha demethylase
Review this target as Lanosterol 14-alpha demethylase, mapped to UniProt P10613. Sequence length is 528 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lanosterol 14-alpha demethylase as ChEMBL target CHEMBL4662933, mapped to UniProt P10613. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Lanosterol 14-alpha demethylase is the right protein anchor across sources, using UniProt P10613 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why vulvovaginal candidiasis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Lanosterol 14-alpha demethylase |
| Target Type | SINGLE PROTEIN |
| Organism | Fungi |
| UniProt | P10613 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Lanosterol 14-alpha demethylase |
| UniProt Accession | P10613 |
| Component Type | Protein |
| Sequence Length | 528 aa |
Lanosterol 14-alpha demethylase
Review this target as Lanosterol 14-alpha demethylase, mapped to UniProt P10613. Sequence length is 528 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Lanosterol 14-alpha demethylase shows approved-linked disease relevance led by vulvovaginal candidiasis. 4 more disease programs remain visible in the same review block.
Start review with vulvovaginal candidiasis because it currently carries approved-linked support. Linked drugs include OTESECONAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.